Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor targets only MP0317’s ability to activate CD40 in a ...

The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of ...

Biomunex's CSO, Dr. Simon Plyte, is invited to present an oral communication during the 11th Annual Oncology Innovation Forum on the 10th of January 2026 in San Francisco (USA). -- The oral ...

CD3 T-cell engagers have the potential to be a cornerstone of cancer treatment. They guide the immune system to find and eliminate cancer cells by binding tumor targets and the CD3 protein on ...

AbCellera today announced new data on its PSMA x CD3 T-cell engagers, presented as a poster at the American Association for Cancer ResearchⓇ 116th Annual Meeting at the McCormick Place Convention ...

Aptevo Therapeutics Inc. has added a preclinical candidate, APVO-455, to its portfolio of CD3-directed candidates built on the CRIS-7-derived CD3 binding domain.